Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of DaxibotulinumtoxinA for Upper Limb Spasticity

Trial Profile

Phase III trial of DaxibotulinumtoxinA for Upper Limb Spasticity

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 17 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 10 May 2021 According to a Revance Therapeutics media release, End-of-Phase 2 meeting with the FDA anticipated in the second half of 2021 for DaxibotulinumtoxinA for Injection for the treatment of adults with upper limb spasticity.
    • 22 Feb 2021 According to a Revance Therapeutics, the company plan to schedule an end-of-Phase 2 meeting with the FDA prior to finalizing a Phase 3 program.
    • 03 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top